In drug development, CYP3A4’s role in metabolizing a wide range of pharmaceuticals is critical. Understanding how a new drug interacts with CYP3A4 can inform its pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME). Drug developers routinely assess whether new compounds are substrates, inhibitors, or inducers of CYP3A4 to predict potential drug-drug interactions and optimize dosing regimens. This knowledge helps in designing safer and more effective therapeutic agents.
